BioSpace News Archive

A recent study has highlighted the need for more stringent Phase II trial protocols on the basis that over 80% of candidate oncology treatments that go into Phase III failed to achieve OS goals.

The U.S. Food and Drug Administration approved COVID-19 vaccine booster shots for all Americans ages 18 and over Friday morning.

In a Bloomberg News survey of 25 large insurers, none described the drug as “medically necessary,” and said Aduhelm was still experimental.

The U.S. Food and Drug Administration has a few PDUFA dates for the Thanksgiving Holiday week. Here’s a look.

Cali Biosciences, a global biopharmaceutical company focused on the research and development of innovative drugs, presented Phase IIa clinical data on its perioperative long-acting ropivacaine, CPL- 01, at the 20th Annual American Society of Regional Anesthesia and Pain Medicine Meeting.

The healthcare industry has witnessed a key development with the advancements in stretcher chairs. These advancements enable clinicians to serve patients in emergencies.

The recent move of the pharmaceutical sector towards enhancing the verification of the legitimacy of drugs and medications has promoted and created new development and growth opportunities in the global RFID in pharmaceutical market.

Chinese biotechnology company Vazyme (688105.SH) recently attended Medica 2021 in Germany—one of the world’s largest events for the medical sector—to accelerate the expansion of its international business.

BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, announced that it has entered into a letter of intent with PRC Clinical, a CRO specializing in clinical trial management, with regard to PRC Clinical providing startup clinical project management activities for the Company’s BRTX-100 Phase 2 clinical trial to treat chronic lumbar disc disease.

Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for GC012F, Gracell’s FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy for the treatment of multiple myeloma.